Profile data is unavailable for this security.
About the company
Bright Green Corporation is a producer and manufacturer of plant-based drugs and active pharmaceutical ingredients (APIs). The Company specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. It plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). It also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. It is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. It also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.
- Revenue in USD (TTM)0.00
- Net income in USD-13.13m
- Incorporated2019
- Employees5.00
- LocationBright Green Corp401 East Las Olas Blvd., Suite 1400FT LAUDERDALE 33301United StatesUSA
- Phone+1 (201) 370-1140
- Fax+1 (302) 636-5454
- Websitehttps://brightgreen.us/
More ▼
Mergers & acquisitions
| Acquired company | BGXX:NAQ since announced | Transaction value |
|---|---|---|
| C2 Wellness Corp | -12.46% | 1.20m |
Data delayed at least 15 minutes, as of May 24 2024 15:49 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OncoCyte Corp | 1.38m | -40.66m | 37.88m | 43.00 | -- | 2.02 | -- | 27.41 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 38.21m | 10.00 | -- | 0.4512 | -- | 90.33 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -25.65m | 38.74m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 38.78m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| DURECT Corp | 8.32m | -23.28m | 39.11m | 48.00 | -- | 4.71 | -- | 4.70 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 39.50m | 73.00 | -- | 1.43 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.13m | 39.92m | 5.00 | -- | 3.54 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 40.12m | 55.00 | -- | 1.35 | -- | 2.37 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.31m | 317.00 | -- | 0.4793 | 30.03 | 0.3353 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.48m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 40.51m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Movano Inc | 852.00k | -27.91m | 40.58m | 30.00 | -- | -- | -- | 47.63 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 41.35m | 4.00 | -- | 6.86 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.38m | 32.00 | -- | 2.46 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 41.61m | 45.00 | -- | 4.76 | -- | 10.60 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 42.11m | 65.00 | -- | 0.5349 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Bright Green Corp's reporting currency: US Dollar USD
5.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.35m | 1.76% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.69m | 1.42% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.46m | 0.77% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.00m | 0.53% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 589.51k | 0.31% |
| The Bank of New York Mellon Corp. (Investment Management)as of 31 Mar 2024 | 163.80k | 0.09% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 148.19k | 0.08% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 137.90k | 0.07% |
| Vanguard Fiduciary Trust Co.as of 31 Mar 2024 | 119.33k | 0.06% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 104.16k | 0.06% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
